Faron Pharmaceuticals Ltd: Holding(s) in Company
TURKU, FI / ACCESS Newswire / June 10, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA) 1. Identity of the …
TURKU, FI / ACCESS Newswire / June 10, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)
Standard form for notification of major holdings
|
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA) |
|||||
|
1. Identity of the issuer: |
|||||
|
2. Reason for the notification (please tick the appropriate box or boxes): |
|||||
|
3. Details of person subject to the notification obligation: |
|||||
|
Name: |
City and country of residence: |
||||
|
4. Full name of shareholder(s) (if different from 3.): |
|||||
|
5. Date on which the threshold was crossed or reached: |
|||||
|
6. Total positions of person(s) subject to the notification obligation: |
|||||
|
% of shares and voting rights |
% of shares and voting rights through financial instruments |
Total of both in % (7.A + 7.B) |
Total number of shares and voting rights of issuer |
||
|
Resulting situation on the date on which threshold was crossed or reached |
0.11 |
10.46 |
10.57 |
206,411,888 |
|
|
Position of previous notification (if applicable) |
0.10 |
9.36 |
9.46 |
||
|
|
|||||||||
|
A: Shares and voting rights |
|||||||||
|
Class/type of |
Number of shares and voting rights |
% of shares and voting rights |
|||||||
|
Direct |
Indirect |
Direct |
Indirect |
||||||
|
FI4000153309 |
0 |
235,532 |
0 |
0.11 |
|||||
|
- |
- |
- |
- |
- |
|||||
|
- |
- |
- |
- |
- |
|||||
|
SUBTOTAL A |
235,532 |
0.11 |
|||||||
|
|
|||||||||
|
B: Financial Instruments according to SMA 9:6a |
|||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Physical or cash settlement |
Number of shares and voting rights |
% of shares and voting rights |
||||
|
Rights of Use |
n/a |
n/a |
n/a |
21,333,422 |
10.34 |
||||
|
15/10/2027 |
n/a |
Cash |
243,327 |
0.12 |
|||||
|
- |
- |
- |
- |
- |
- |
||||
|
SUBTOTAL B |
21,576,749 |
10.46 |
|||||||
|
|
|||||||||
|
8. Information in relation to the person subject to the notification obligation (please tick the applicable box): |
|||
|
Name |
% of shares and voting rights |
% of shares and voting rights through financial instruments |
Total of both |
|
Bank of America Corporation |
|||
|
NB Holdings Corporation |
|||
|
BofAML Jersey Holdings Limited |
|||
|
BofAML EMEA Holdings 2 Limited |
|||
|
Bofa Securities, Inc |
10.34% |
10.34% |
|
|
9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting
rights as of |
|||
|
10. Additional information: |
|||
Done at London, United Kingdom on 5.6.2026.
SOURCE: Faron Pharmaceuticals
View the original press release on ACCESS Newswire
The Faron Pharmaceuticals Oy Stock at the time of publication of the news with a raise of +1,12 % to 0,496EUR on Lang & Schwarz stock exchange (10. Juni 2026, 19:03 Uhr).

